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IMPORTANCE Anticholinergic medicines have short-term cognitive adverse effects, but it
is uncertain whether long-term use of these drugs is associated with an increased risk of
dementia.
OBJECTIVE To assess associations between anticholinergic drug treatments and risk of
dementia in persons 55 years or older.
DESIGN, SETTING, AND PARTICIPANTS This nested case-control study took place in general
practices in England that contributed to the QResearch primary care database. The study
evaluated whether exposure to anticholinergic drugs was associated with dementia risk in
58 769 patients with a diagnosis of dementia and 225 574 controls 55 years or older matched
by age, sex, general practice, and calendar time. Information on prescriptions for 56 drugs
with strong anticholinergic properties was used to calculate measures of cumulative
anticholinergic drug exposure. Data were analyzed fromMay 2016 to June 2018.
EXPOSURES The primary exposure was the total standardized daily doses (TSDDs) of
anticholinergic drugs prescribed in the 1 to 11 years prior to the date of diagnosis of dementia
or equivalent date in matched controls (index date).
MAIN OUTCOMES ANDMEASURES Odds ratios (ORs) for dementia associatedwith cumulative
exposure to anticholinergic drugs, adjusted for confounding variables.
RESULTS Of the entire study population (284 343 case patients andmatched controls),
179 365 (63.1%) were women, and themean (SD) age of the entire population was 82.2 (6.8)
years. The adjusted OR for dementia increased from 1.06 (95% CI, 1.03-1.09) in the lowest
overall anticholinergic exposure category (total exposure of 1-90 TSDDs) to 1.49 (95% CI,
1.44-1.54) in the highest category (>1095 TSDDs), compared with no anticholinergic drug
prescriptions in the 1 to 11 years before the index date. There were significant increases in
dementia risk for the anticholinergic antidepressants (adjusted OR [AOR], 1.29; 95% CI,
1.24-1.34), antiparkinson drugs (AOR, 1.52; 95% CI, 1.16-2.00), antipsychotics (AOR, 1.70; 95%
CI, 1.53-1.90), bladder antimuscarinic drugs (AOR, 1.65; 95% CI, 1.56-1.75), and antiepileptic
drugs (AOR, 1.39; 95% CI, 1.22-1.57) all for more than 1095 TSDDs. Results were similar when
exposures were restricted to exposure windows of 3 to 13 years (AOR, 1.46; 95% CI, 1.41-1.52)
and 5 to 20 years (AOR, 1.44; 95% CI, 1.32-1.57) before the index date for more than 1095
TSDDs. Associations were stronger in cases diagnosed before the age of 80 years. The
population-attributable fraction associated with total anticholinergic drug exposure during
the 1 to 11 years before diagnosis was 10.3%.
CONCLUSIONS AND RELEVANCE Exposure to several types of strong anticholinergic drugs is
associated with an increased risk of dementia. These findings highlight the importance of
reducing exposure to anticholinergic drugs in middle-aged and older people.
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A n estimated 47 million people worldwide were livingwith dementia in 2015,1 while in the United Statesaround 5.7million people have Alzheimer dementia.2
Modifiable risk factors, including hypertension, hearing loss,
depression, diabetes, and smoking, account for around 35%
of dementia cases.1 Anticholinergic drugs are another poten-
tiallymodifiable risk factor. This broad group of drugs acts by
blocking theneurotransmitter acetylcholine in the central and
peripheral nervous system and includes some antihista-
mines, antidepressants, andmedications for gastrointestinal
and bladder disorders. These medicines can have short-term
adverse effects, including confusionandmemory loss inolder
people,3-6 but it is less certain whether long-term use in-
creases the risk of dementia.
Observational studiesof anticholinergicdrugsanddemen-
tia risk7-10 have generally been relatively small, only assessed
short-termexposure, orwere subject to recall bias.These stud-
ies were also susceptible to protopathic bias because they did
not account for anticholinergic drugs beingprescribed to treat
early symptomsofdementiabeforediagnosis.Acohort study11
that reducedprotopathicbiasbyexcludingprescriptions in the
final year of follow-up found that higher cumulative anticho-
linergic drugusewas associatedwith a significantly increased
risk of dementia but had limited power for analysis of sepa-
rate typesof anticholinergicdrug.A recent larger study12 found
varying risks associated with different types of anticholiner-
gic drugs and concluded that further research should exam-
ine individual anticholinergic drug classes.
This study was designed to assess the association be-
tweencumulative anticholinergic druguse and riskofdemen-
tia in a large, representative British population. The study ob-
jectives were to estimate dementia risks associated with
different types of anticholinergicmedication including analy-
ses of prescriptions up to 20 years before diagnosis.
Methods
Study Design
This was a nested case-control study within a cohort of pa-
tients registeredwithpractices inEngland contributing to the
QResearch database (version 41). QResearch is an anony-
mized research database of more than 30million individuals
inover 1500general practices that includesdata recordedpro-
spectively from routine health care. The data include demo-
graphic information,medical diagnoses, prescriptions, refer-
rals, laboratory results, and clinical values.
Thestudywasapproved inaccordancewith theagreedpro-
cedure with the East Midlands Derby Research Ethics Com-
mittee, waiving written informed consent for deidentified
patient data.
Selection of Cases and Controls
The base cohort included patients 55 years and older regis-
tered during the study period (January 1, 2004, to January 31,
2016)without a diagnosis of dementia at study entry, defined
as the latest of the study start date (January 1, 2004), the pa-
tient’s 55thbirthday,dateof registrationwith thepracticeplus
1 year, or date when the practice computer system was in-
stalled plus 1 year. The cohort were followed up until the ear-
liest date of death, transfer to another practice, or the study
end date (January 31, 2016).
Case patients were those diagnosed with dementia dur-
ing follow-up, identified using clinical codes recorded in the
practice recordsor linkedOfficeofNationalStatisticsdeath rec-
ords. Patients with prescriptions for acetylcholinesterase-
inhibitingdrugs (donepezil, galantamine,memantine, and riv-
astigmine) butwithout a recordeddiagnosis of dementiawere
also included because these drugs are licensed only for pa-
tients with dementia. Case patients with diagnostic codes for
specific subtypes of dementia associated with Huntington
disease, Parkinson disease, Creutzfeldt-Jakob disease, or hu-
man immunodeficiencyvirus (HIV)wereexcluded,aswerepa-
tients diagnosed with Parkinson disease, Huntington dis-
ease, or multiple sclerosis to reduce indication bias.
Eachcasepatientwasmatched to5 controls byage (within
1 year), sex, general practice, and calendar time using inci-
dencedensity sampling.13 The indexdate for controlswas the
dateofdiagnosis for theirmatchedcasepatient. Controlswere
excluded if they had a diagnosis of Parkinson disease, Hun-
tington disease, or multiple sclerosis.
For the primary analyses, case patients and controlswere
only included if theyhadat least 11 yearsof recordeddataprior
to the indexdate, so that anticholinergic drug exposure could
be assessed over a complete period of 10 years (excluding the
1-year period prior to the index date).
Exposures
There is incomplete consensus on which drugs are consid-
ered as having anticholinergic properties. We used the ap-
proach of Gray et al,11 which included drugs identified as hav-
ingstronganticholinergicpropertiesbytheAmericanGeriatrics
Society 2012Beers Criteria Update Expert Panel.14We also in-
cludedadditionaldrugs in theBeers2015updated list of strong
anticholinergic drugs,15 drugs listed as having a high anticho-
linergicburden in theAnticholinergicCognitiveBurdenscale,16
or identified as high-potency anticholinergics in a systematic
review,17 and some furtherdrugs identified ashaving substan-
tial anticholinergic properties in the British National Formu-
lary; thesemay have been omitted in previous studies owing
Key Points
Question Is the risk of dementia among persons 55 years or older
associated with the use of different types of anticholinergic
medication?
Findings In this nested case-control study of 58 769 patients with
a diagnosis of dementia and 225 574matched controls, there were
statistically significant associations of dementia risk with exposure
to anticholinergic antidepressants, antiparkinson drugs,
antipsychotic drugs, bladder antimuscarinics, and antiepileptic
drugs after adjusting for confounding variables.
Meaning The associations observed for specific types of
anticholinergic medication suggest that these drugs should be
prescribed with caution in middle-aged and older adults.
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to their unavailability in the country where the study origi-
nated. eTable 1 in the Supplement shows the 56 anticholiner-
gic drugs included in the study with details of their basis for
inclusion.
We extracted details of prescriptions for the included an-
ticholinergic drugs. To reduce protopathic biases, we did not
includeprescriptions issued in the year before the indexdate.
In 2 additional analyses, we only included prescriptions is-
sued up to 3 and up to 5 years before diagnosis.
The primary exposure variable was total cumulative an-
ticholinergic drug exposure, which combined the different
typesofanticholinergicmedicationsbasedonthemethodused
byGray et al.11 This involved calculating the total dose of each
prescription bymultiplying the number of tablets prescribed
by thedoseper tablet (or equivalent for solutions, inhalers, in-
jections, or patches). These valueswere thendividedbymini-
mumeffectivedailydosevalues recommended foruse inolder
adults to give a number of standardized daily doses for each
prescription.Weusedminimumeffectivedosevalues fromthe
Geriatric DosageHandbook18where available, and for the ad-
ditional drugswe used the lowest recommended dose values
(inolderpeople if stated) in theBritishNationalFormulary (see
eTable 1 in the Supplement).We summed these standardized
values over all anticholinergic prescriptions in the exposure
time windows of interest to obtain total standardized daily
doses (TSDDs) for each patient.
We also calculated TSDDs for each type of anticholinergic
drugbasedon itsmain indication (antihistamines, antidepres-
sants, antivertigo/antiemetic drugs, antiparkinson agents,
antipsychotics, bladder antimuscarinics, skeletal muscle re-
laxants, gastrointestinal antispasmodics, antiarrhythmics, an-
tiepileptic drugs, and antimuscarinic bronchodilators). As a
sensitivityanalysisweusedWorldHealthOrganization (WHO)-
defined daily dose (DDD) values (https://www.whocc.no/atc_
ddd_index/) to standardize the prescribed doses.
Confounding Variables
We accounted for potential confounding variables identified
as risk factors for dementia or indications for anticholinergic
druguse,19-25 includingbodymass index, calculatedasweight
in kilograms divided by height inmeters squared,20 smoking
status,26 alcohol consumption,27 Townsend deprivation
score,21 self-assigned ethnic group,28 comorbidities (coro-
nary heart disease, atrial fibrillation, heart failure, hyperten-
sion, hyperlipidemia, diabetes, stroke, subarachnoid hemor-
rhage, transient ischemicattack, renal failure, asthma, chronic
obstructive pulmonary disease, anxiety, bipolar disorder, de-
pression,Downsyndrome, severe learningdifficulties, schizo-
phrenia, severe head injury, and cognitive decline/memory
loss), and use of other medications (antihypertensive drugs,
aspirin, hypnotic and anxiolytic drugs, nonsteroidal antiin-
flammatorydrugs, statins). These variableswere evaluated at
the start of the exposure window for the primary analysis.
Statistical Analysis
We used conditional logistic regression to estimate odds ra-
tios (ORs) adjusted for the confounding variables. The expo-
sure window in themain analyses comprised the 1 to 11 years
before the index date. We categorized the anticholinergic
exposure variable into 5 categories (0, 1-90, 91-365, 366-
1095, and >1095 TSDDs).11 Similarlywe assessed associations
for the 11 separate typesof anticholinergicdrug.Datawereana-
lyzed fromMay 2016 to June 2018.
Wecarriedout subgroupanalyses and interaction tests by
age at index date (younger than 80 years and 80 years and
older), by sex, and separately in case patients diagnosedwith
Alzheimer disease (includingmixed), vascular dementia, and
other or unspecified types of dementia with their respective
matched controls.
We carried out the following sensitivity analyses:
(1) we assessed anticholinergic exposure over a time window
of 3 to 13 years before the index date by excluding prescrip-
tions in the 3 years before the index date;
(2) we assessed anticholinergic exposure over a timewindow
of 5 to 20 years before the index date to further reduce poten-
tialprotopathicbiasesandtoassessassociations for longer term
exposure;
(3) we removed those anticholinergic drugs not included by
Gray et al11 so we could directly compare associations;
(4) we used multiple imputation by chained equations to re-
placemissingvalues for bodymass index, smoking status, and
alcoholconsumption.Wecreated10multiply imputeddatasets
and combined results using Rubin rules29; and
(5) we repeated the analyses using the cumulative exposure
variable standardized byWHO DDD values.
We calculated population-attributable fractions by com-
biningadjustedoddsratios (AORs)withtheproportionsofcases
in thedifferentcategoriesofanticholinergicdrugexposure.30,31
We used P < .01 (2-tailed) to determine statistical signifi-
cance. We used Stata (version 15.1) for all analyses.
Results
Thebasecohort comprised3638582 individualsaged55 to100
years. During a total of 20005739 person-years of follow-up,
128 517 peoplewere diagnosedwith dementia. After applying
exclusion criteria, 58 769 case patients and 225 574 matched
controls were eligible for inclusion (eFigure 1 in the Supple-
ment). Case patients had a mean (SD) age of 82.4 (7.0) years
atdiagnosis, and63.1%(37 105)werewomen (Table 1); eTable2
in the Supplement details that in the 36666 cases where de-
mentia type was recorded, 22034 (60.1%) patients had a di-
agnosis ofAlzheimerdisease (includingmixed), 13 313 (36.3%)
hadadiagnosisofvasculardementia, and1319 (3.6%)hadother
types of dementia.
Table 2 presents information on comorbidities and pre-
scribed medications. Prevalence values were slightly higher
in case patients than in controls for all the comorbidities and
prescribed medications.
Anticholinergic Drug Exposure
In the 1 to 11 years before the index date, 56.6% of case pa-
tients (33 253) and 51.0% of controls (115 096) were pre-
scribed at least 1 anticholinergic drug,with amedian of 6 pre-
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scriptions in casepatients and4 in controls (Table 3). Themost
frequently prescribed types of anticholinergic drugswere an-
tidepressants (27.1% of case patients, 23.3% of controls), an-
tivertigo/antiemeticdrugs (23.8%ofcasepatients,21.7%ofcon-
trols), andbladderantimuscarinicdrugs (11.7%ofcasepatients,
8.3% of controls) (see eFigure 2 in the Supplement). eTable 3
in theSupplementprovidesdescriptive information for the56
different anticholinergicdrugs included in the study. eTables4
and 5 in the Supplement present descriptive information on
anticholinergic drugs prescribed in the 3 to 13 years and 5 to
20 years before the index date, respectively.
AssociationsWith Dementia
The AOR associated with total cumulative anticholinergic
exposure in the 1 to 11 years before the index date increased
from 1.06 (95% CI, 1.03-1.09) for 1 to 90 TSDDs to 1.49 (95%
CI, 1.44-1.54) for more than 1095 TSDDs, compared with non-
use (Table 4). Results were similar but with slightly lower
ORs when restricted to the 3 to 13 and 5 to 20 years before
the index date; for example, for the 5 to 20 years before the
Table 1. Demographic Characteristics of Case Patients
andMatched Controls
Characteristic
Study Participants, No. (%)
Case Patients
(n = 58 769)
Controls
(n = 225 574)
Age at diagnosis of
dementia/index date,
mean (SD), y
82.4 (7.0) 82.1 (6.8)
Age at diagnosis/index date, y
55-64 685 (1.2) 2577 (1.1)
65-74 6983 (11.9) 26 952 (12.0)
75-84 26 610 (45.3) 106 705 (47.3)
85-94 23 075 (39.3) 86 148 (38.2)
≥95 1416 (2.4) 3192 (1.4)
Men 21 664 (36.9) 83 314 (36.9)
Women 37 105 (63.1) 142 260 (63.1)
Ethnicity recorded 45 008 (76.6) 174 660 (77.4)
Ethnicity
White/not recorded 57 004 (97.0) 220 081 (97.6)
Indian 341 (0.6) 1302 (0.6)
Pakistani 138 (0.2) 431 (0.2)
Bangladeshi 107 (0.2) 271 (0.1)
Other Asian 110 (0.2) 444 (0.2)
Caribbean 629 (1.1) 1726 (0.8)
Black African 99 (0.2) 292 (0.1)
Chinese 43 (0.1) 217 (0.1)
Other 298 (0.5) 810 (0.4)
Townsend deprivation
score, fifthsa
1 (least deprived) 15 802 (26.9) 65 507 (29.0)
2 14 628 (24.9) 57 835 (25.6)
3 13 003 (22.1) 48 432 (21.5)
4 9558 (16.3) 34 310 (15.2)
5 (most deprived) 5701 (9.7) 19 244 (8.5)
BMI recorded 53 518 (91.1) 204 764 (90.8)
BMI, mean (SD) 26.5 (4.4) 26.8 (4.4)
Smoking status
Nonsmoker 33 936 (57.7) 132 732 (58.8)
Ex-smoker 16 285 (27.7) 61 168 (27.1)
Light smoker
(1-9 cigarettes/d)
4455 (7.6) 15 795 (7.0)
Moderate smoker
(10-19 cigarettes/d)
1795 (3.1) 6443 (2.9)
Heavy smoker
(≥20 cigarettes/d)
1069 (1.8) 3714 (1.7)
Not recorded 1229 (2.1) 5722 (2.5)
Alcohol intake
Nondrinker 20 193 (34.4) 73 287 (32.5)
Trivial (<1 U/d) 19 253 (32.8) 75 330 (33.4)
Light (1-2 U/d) 6928 (11.8) 27 494 (12.2)
Moderate (3-6 U/d) 6117 (10.4) 24 443 (10.8)
Heavy (7-9 U/d) 468 (0.8) 1510 (0.7)
Very heavy (>9 U/d) 124 (0.2) 356 (0.2)
Not recorded 5686 (9.7) 23 154 (10.3)
Missing values for
BMI, smoking status,
or alcohol intake
7770 (13.2) 30 758 (13.6)
Abbreviations: BMI, bodymass index, calculated as weight in kilograms divided
by height in meters squared; U/d, units of alcohol per day.
a Deprivation fifthsusingquintiles for theentireQResearchdatabaseacrossall ages.
Table 2. Prevalence of Comorbidities and PrescribedMedications
in Case Patients andMatched Controls
Characteristic
Study Participants, No. (%)
Case Patients
(n = 58 769)
Controls
(n = 225 574)
Comorbiditya
Hypertension 19 907 (33.9) 73 267 (32.5)
Stroke 1483 (2.5) 3936 (1.7)
Transient ischemic attack 1717 (2.9) 5110 (2.3)
Subarachnoid hemorrhage 177 (0.3) 453 (0.2)
Coronary heart disease 7778 (13.2) 25 872 (11.5)
Heart failure 990 (1.7) 3149 (1.4)
Atrial fibrillation 1774 (3.0) 5900 (2.6)
Hyperlipidemia 4123 (7.0) 13 986 (6.2)
Diabetes 4612 (7.9) 12 929 (5.7)
Anxiety 3693 (6.3) 12 348 (5.5)
Depression 8106 (13.8) 26 086 (11.6)
Bipolar disorder 152 (0.3) 262 (0.1)
Schizophrenia 265 (0.5) 559 (0.3)
Severe head injury 211 (0.4) 689 (0.3)
Severe learning difficulties 6 (0.0) 5 (0.0)
Down syndrome 54 (0.1) 2 (0.0)
Cognitive decline 184 (0.3) 364 (0.2)
Asthma 4482 (7.6) 16 243 (7.2)
Chronic obstructive
pulmonary disease
1558 (2.7) 5228 (2.3)
Renal disease 176 (0.3) 594 (0.3)
Medicationsa
Aspirin 12 162 (20.7) 40 329 (17.9)
Nonsteroidal antiinflammatory
drugs
21 222 (36.1) 79 412 (35.2)
Antihypertensives 25 377 (43.2) 92 708 (41.1)
Statins 7804 (13.3) 25 218 (11.2)
Anxiolytic 2756 (4.7) 8822 (3.9)
Hypnotic 4749 (8.1) 15 855 (7.0)
a Comorbidities andmedications assessed at index date minus 11 years.
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index date the AORwas 1.44 (95% CI, 1.32-1.57) for more than
1095 TSDDs (Table 4).
Among specific types of anticholinergic drugs therewere
significant increases in risk associatedwithuse of antidepres-
sants, antiparkinson drugs, antipsychotics, bladder antimus-
carinics, and antiepileptic drugs (Table 5). Adjusted odds ra-
tios in thehighest exposure category (>1095TSDDs)were 1.29
(95% CI, 1.24-1.34) for antidepressants, 1.52 (95% CI, 1.16-
2.00) for antiparkinson drugs, 1.70 (95% CI, 1.53-1.90) for an-
tipsychotics, 1.65 (95% CI, 1.56-1.75) for bladder antimusca-
rinics, and 1.39 (95% CI, 1.22-1.57) for antiepileptic drugs, all
compared with nonuse. For antivertigo/antiemetic drugs, as
detailed in Table 5, there was a significantly increased risk
associatedwith 366 to 1095TSDDs, but not for thehighest ex-
posure category. There were no significant increases in risk
associated with antihistamines, skeletal muscle relaxants,
gastrointestinal antispasmodics, antiarrhythmics, or antimus-
carinic bronchodilators, although the numbers of patients
exposed were small for skeletal muscle relaxants and antiar-
rhythmics. Patterns of risk were similar in the 3- to 13- and 5-
to 20-year exposure windows (eTable 6 in the Supplement),
except forantipsychoticdrugexposure in the5- to20-yearwin-
dow,where therewere no statistically significant increases in
risk; theAORformore than 1095TSDDswas 1.23 (95%CI,0.93-
1.62). For some drug types, numbers were too small to allow
analysis for the 5 to 20 years before the index date (eTable 7
in the Supplement).
The population-attributable fraction associatedwith total
anticholinergicdrugexposureduring the 1 to 11yearsbeforedi-
agnosiswas 10.3%.For the3 to 13yearsbeforediagnosis, itwas
9.0%, and it was 9.7% for the 5 to 20 years before diagnosis.
Additional Analyses
There were stronger associations in case patients diagnosed
beforeage80years thanat80yearsorolder, both for totaldrug
exposure and for antidepressants, antipsychotics, and blad-
der antimuscarinics (eTable8 in theSupplement). For total cu-
mulativeexposure, theAORformore than1095TSDDswas 1.81
(95% CI, 1.71-1.91) in cases diagnosed before age 80 years,
whereas it was 1.35 (95% CI, 1.30-1.40) in cases diagnosed at
80yearsorolder.Associationswere similar inmenandwomen
(eTable 9 in the Supplement).
Adjustedodds ratiosweregenerallyhigher forvascularde-
mentia than Alzheimer disease (eTable 10 in the Supple-
ment); for example, in the 1- to 11-year exposure window, the
AOR formore than 1095TSDDswas 1.68 (95%CI, 1.57-1.79) for
vascular dementia, and 1.37 (95%CI, 1.30-1.44) for Alzheimer
disease.
Results were similar when DDD values were used to cal-
culatecumulativeexposure (eTable 12 in theSupplement). Sen-
sitivity analyses usingmultiply imputeddata (eTable 13 in the
Supplement) or restricted to anticholinergic drugs included in
the study byGray et al11 (eTable 14 in the Supplement) did not
change study findings.
Table 3. Numbers of Case Patients and Controls Prescribed Different Types of Anticholinergic Drugs in the 1 to 11 Years Before the Index Date
Anticholinergic
Drug Group
Case Patients (n = 58 769) Controls (n = 225 574)
No. (%) Median (IQR) No. (%) Median (IQR)
No. With
Prescriptions
Total
Prescriptions
No. of
Prescriptionsa Total Dosea,b
No. With
Prescriptions
Total
Prescriptions
No. of
Prescriptionsa Total Dosea,b
Any anticholinergic
drugs
33 253 (56.6) 952 263
(100)
6 (2-34) 214 (42-1531) 115 096
(51.0)
2 504 790 (100) 4 (1-22) 136 (30-982)
Antihistamines 6457 (11.0) 34 151 (3.6) 1 (1-3) 30 (23-84) 23 145 (10.3) 117 271 (4.7) 1 (1-3) 30 (27-84)
Antidepressants 15 938 (27.1) 427 489
(44.9)
6 (1-35) 280 (62-1876) 52 560 (23.3) 1 141 284 (45.6) 4 (1-25) 196 (56-1350)
Antivertigo/
antiemetic drugs
13 969 (23.8) 79 673 (8.4) 2 (1-4) 20 (9-56) 48 990 (21.7) 249 214 (9.9) 1 (1-3) 19 (9-50)
Antiparkinson
drugs
292 (0.5) 16 498 (1.7) 31 (3-91) 879
(105-3274)
527 (0.2) 25 412 (1.0) 22 (2-73) 541 (48-2333)
Antipsychotic drugs 1812 (3.1) 69 895 (7.3) 11 (2-51) 756
(119-3751)
3400 (1.5) 109 180 (4.4) 8 (1-46) 490 (84-2894)
Bladder
antimuscarinic
drugs
6864 (11.7) 170 064
(17.9)
8 (2-32) 330 (60-1461) 18 778 (8.3) 362 677 (14.5) 5 (1-23) 198 (56-1120)
Skeletal muscle
relaxants
429 (0.7) 1361 (0.1) 1 (1-2) 23 (16-45) 1568 (0.7) 5202 (0.2) 1 (1-2) 24 (17-42)
Gastrointestinal
antispasmodic
drugs
4036 (6.9) 29 320 (3.1) 1 (1-4) 30 (13-120) 15 481 (6.9) 101 268 (4.0) 1 (1-3) 28 (13-112)
Antiarrhythmic
drugs
49 (0.1) 2569 (0.3) 31 (5-88) 882
(175-2345)
172 (0.1) 8142 (0.3) 37 (5-77) 1148 (150-2436)
Antiepileptic drugs 1411 (2.4) 41 360 (4.3) 4 (1-39) 153 (42-2240) 4492 (2.0) 97 180 (3.9) 2 (1-20) 80 (30-970)
Antimuscarinic
bronchodilator
drugs
3878 (6.6) 79 883 (8.4) 8 (2-29) 300 (60-1330) 13 996 (6.2) 287 960 (11.5) 8 (2-29) 330 (67-1333)
Abbreviations: IQR, interquartile range; TSDD, total standardized daily dose.
a In patients with 1 or more prescriptions for drug.
b Cumulative dose calculated using TSDDs in exposure window.
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Discussion
This large, nested case-control study found an increased risk
of dementia associated with anticholinergic medication use.
Associations were strongest for the anticholinergic antide-
pressants, bladder antimuscarinics, antipsychotics, and
antiepileptic drugs. Associations were also stronger in cases
diagnosed before the age of 80 years and in cases diagnosed
with vascular dementia rather than with Alzheimer disease.
There were no significantly increased risks for antihista-
mines, gastrointestinal antispasmodics, antimuscarinic bron-
chodilators, antiarrhythmics, or skeletalmuscle relaxants, al-
though the numbers of patients prescribed skeletal muscle
relaxants and antiarrhythmic drugswere small, giving impre-
cise estimates.
Therewas nearly a 50% increased odds of dementia asso-
ciated with total anticholinergic exposure of more than 1095
TSDDswithin a 10-year period,which is equivalent to 3 years’
daily use of a single strong anticholinergic medication at the
minimumeffective dose recommended for older people. This
observational studyhas shownassociations, but is not able to
evaluate causality. However, if this association is causal, the
population-attributable fractions indicate that around 10%of
dementiadiagnosesareattributable toanticholinergicdrugex-
posure, which would equate, for example, to around 20000
of the 209600 new cases of dementia per year in the United
Kingdom.32Thisproportion is sizeable and is comparablewith
estimates for othermodifiable risk factors for dementia, such
as 5% formidlife hypertension, 3% for diabetes, 14% for later-
life smoking, and 6.5% for physical inactivity.1
The finding of more pronounced associations for vascu-
lar dementia than for other types is novel. It raises questions
about themechanismsbywhichanticholinergicdrugsmay in-
crease theriskof subsequentdementia.Thesemay includevas-
cular and inflammatory changes,33,34 as well as the more ob-
viousmechanismofchronic cholinergicdepletion.Perhaps the
mechanism underlying the potential effects of anticholiner-
gicdrugs isnot solely throughblockingacetylcholineandcaus-
ing an excess of Alzheimer disease, so future research should
give consideration to possible mechanisms.
We included a large representative sample of people di-
agnosedwithdementia andmatchedcontrols.All eligible case
patients and controls were included, so there is no selection
Table 4. Risk of Dementia AssociatedWith Total Cumulative Use of Any Type of Anticholinergic Drugs Among Study Patients
Exposure Category
Study Participants, No (%) OR (95% CI)
Case Patients Controls Unadjusted Adjusteda
Exposure in the 1 to 11 Years Before Index Date
Patients, No. 58 769 225 574 NA NA
Cumulative use (TSDDs)
Nonuse 25 516 (43.4) 110 478 (49.0) 1 [Reference] 1 [Reference]
1-90 12 546 (21.4) 50 220 (22.3) 1.09 (1.06-1.11) 1.06 (1.03-1.09)
91-365 6370 (10.8) 23 302 (10.3) 1.20 (1.16-1.24) 1.17 (1.13-1.21)
366-1095 4537 (7.7) 14 138 (6.3) 1.40 (1.35-1.46) 1.36 (1.30-1.41)
>1095 9800 (16.7) 27 436 (12.2) 1.58 (1.53-1.62) 1.49 (1.44-1.54)
Exposure in the 3 to 13 Years Before Index Date
Patients, No. 45 621 169 020 NA NA
Cumulative use (TSDDs)
Nonuse 20 545 (45.0) 84 676 (50.1) 1 [Reference] 1 [Reference]
1-90 9749 (21.4) 37 553 (22.2) 1.07 (1.05-1.10) 1.05 (1.02-1.08)
91-365 5079 (11.1) 17 470 (10.3) 1.22 (1.17-1.26) 1.18 (1.13-1.23)
366-1095 3286 (7.2) 10 423 (6.2) 1.32 (1.27-1.38) 1.25 (1.19-1.31)
>1095 6962 (15.3) 18 898 (11.2) 1.55 (1.50-1.60) 1.46 (1.41-1.52)
Exposure in the 5 to 20 Years Before Index Date
Patients, No. 8283 27 200 NA NA
Cumulative use (TSDDs)
Nonuse 3335 (40.3) 12 281 (45.2) 1 [Reference] 1 [Reference]
1-90 1924 (23.2) 6531 (24.0) 1.09 (1.02-1.16) 1.07 (1.00-1.15)
91-365 1003 (12.1) 3278 (12.1) 1.15 (1.06-1.25) 1.11 (1.01-1.21)
366-1095 699 (8.4) 1811 (6.7) 1.44 (1.31-1.59) 1.33 (1.20-1.48)
>1095 1322 (16.0) 3299 (12.1) 1.52 (1.40-1.64) 1.44 (1.32-1.57)
Abbreviations: OR, odds ratio; NA, not applicable; TSDD, total standardized
daily dose.
a Adjusted for bodymass index, calculated as weight in kilograms divided by
height in meters squared, smoking status, alcohol consumption, Townsend
deprivation score, ethnic group, coronary heart disease, atrial fibrillation, heart
failure, hypertension, hyperlipidemia, diabetes (type 1 and type 2), stroke,
transient ischemic attack, subarachnoid hemorrhage, renal disease, asthma,
chronic obstructive pulmonary disease, anxiety, depression, bipolar disorder,
schizophrenia, severe head injury, cognitive decline/memory loss,
antihypertensive drugs, aspirin, hypnotics, anxiolytic drugs, nonsteroidal
antiinflammatory drugs, statins, and with matching by age, sex, general
practice, and calendar time.
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Table 5. ORs for Total Cumulative Use of Different Types of Anticholinergic Drugs
in the 1 to 11 Years Before the Index Date
Drug Type
Study Participants, No. (%) Odds Ratio (95%CI)
Case Patients
(n = 58 769)
Controls
(n = 225 574) Unadjusted
Adjusted for the
Other Drug Typesa Fully Adjustedb
Antihistamines, TSDDs
Nonuse 52 312 (89.0) 202 429 (89.7) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 4987 (8.5) 18 187 (8.1) 1.05 (1.02-1.09) 1.02 (0.98-1.05) 1.03 (0.99-1.07)
91-365 923 (1.6) 3105 (1.4) 1.14 (1.06-1.23) 1.06 (0.99-1.15) 1.03 (0.95-1.12)
366-1095 280 (0.5) 1022 (0.5) 1.06 (0.93-1.22) 0.98 (0.85-1.12) 1.02 (0.88-1.18)
>1095 267 (0.5) 831 (0.4) 1.22 (1.06-1.41) 1.14 (0.99-1.31) 1.14 (0.98-1.34)
Antidepressants, TSDDs
Nonuse 42 831 (72.9) 173 014 (76.7) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 5098 (8.7) 19 402 (8.6) 1.08 (1.04-1.11) 1.04 (1.01-1.08) 1.02 (0.98-1.06)
91-365 3463 (5.9) 11 931 (5.3) 1.20 (1.15-1.24) 1.14 (1.10-1.19) 1.12 (1.07-1.17)
366-1095 2227 (3.8) 6749 (3.0) 1.35 (1.29-1.42) 1.27 (1.20-1.33) 1.25 (1.18-1.32)
>1095 5150 (8.8) 14 478 (6.4) 1.47 (1.42-1.52) 1.34 (1.29-1.39) 1.29 (1.24-1.34)
Antivertigo/Antiemetics, TSDDs
Nonuse 44 800 (76.2) 176 584 (78.3) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 11 427 (19.4) 41 159 (18.3) 1.10 (1.07-1.12) 1.06 (1.03-1.08) 1.05 (1.02-1.08)
91-365 1574 (2.7) 5026 (2.2) 1.23 (1.16-1.31) 1.14 (1.08-1.21) 1.14 (1.07-1.21)
366-1095 617 (1.1) 1659 (0.7) 1.47 (1.34-1.61) 1.33 (1.21-1.47) 1.41 (1.27-1.56)
>1095 351 (0.6) 1146 (0.5) 1.20 (1.06-1.35) 1.06 (0.94-1.20) 1.08 (0.94-1.24)
Antiparkinson Agents, TSDDs
Nonuse 58 477 (99.5) 225 047 (99.8) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 68 (0.1) 179 (0.1) 1.43 (1.08-1.90) 1.04 (0.78-1.38) 1.01 (0.73-1.39)
91-365 50 (0.1) 59 (0) 3.29 (2.25-4.81) 2.07 (1.40-3.05) 1.68 (1.09-2.58)
366-1095 39 (0.1) 71 (0) 2.08 (1.40-3.09) 1.29 (0.86-1.94) 1.03 (0.66-1.61)
>1095 135 (0.2) 218 (0.1) 2.39 (1.93-2.97) 1.61 (1.29-2.03) 1.52 (1.16-2.00)
Antipsychotics, TSDDs
Nonuse 56 957 (96.9) 222 174 (98.5) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 388 (0.7) 882 (0.4) 1.71 (1.51-1.93) 1.56 (1.38-1.76) 1.44 (1.25-1.66)
91-365 332 (0.6) 695 (0.3) 1.90 (1.66-2.17) 1.67 (1.46-1.91) 1.41 (1.21-1.65)
366-1095 304 (0.5) 490 (0.2) 2.45 (2.12-2.83) 2.15 (1.85-2.49) 2.09 (1.76-2.47)
>1095 788 (1.3) 1333 (0.6) 2.29 (2.09-2.50) 1.89 (1.72-2.07) 1.70 (1.53-1.90)
Bladder Antimuscarinics, TSDDs
Nonuse 51 905 (88.3) 206 796 (91.7) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 2139 (3.6) 7005 (3.1) 1.21 (1.15-1.27) 1.18 (1.12-1.24) 1.19 (1.13-1.26)
91-365 1417 (2.4) 4078 (1.8) 1.38 (1.30-1.47) 1.33 (1.25-1.41) 1.35 (1.27-1.45)
366-1095 1244 (2.1) 2941 (1.3) 1.71 (1.59-1.83) 1.63 (1.52-1.74) 1.65 (1.53-1.78)
>1095 2064 (3.5) 4754 (2.1) 1.73 (1.64-1.82) 1.65 (1.57-1.74) 1.65 (1.56-1.75)
Skeletal Muscle Relaxants, TSDDs
Nonuse 58 340 (99.3) 224 006 (99.3) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 372 (0.6) 1380 (0.6) 1.08 (0.96-1.22) 1.01 (0.89-1.14) 0.98 (0.86-1.11)
91-365 39 (0.1) 115 (0.1) 1.38 (0.95-1.99) 1.17 (0.81-1.70) 1.12 (0.77-1.65)
366-1095 9 (0) 41 (0) 0.90 (0.44-1.88) 0.84 (0.40-1.75) 0.99 (0.46-2.10)
>1095 9 (0) 32 (0) 1.09 (0.52-2.29) 0.90 (0.42-1.91) 1.10 (0.47-2.55)
Gastrointestinal Antispasmodics, TSDDs
Nonuse 54 733 (93.1) 210 093 (93.1) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 2765 (4.7) 10 914 (4.8) 0.97 (0.93-1.01) 0.90 (0.86-0.94) 0.90 (0.85-0.94)
91-365 722 (1.2) 2686 (1.2) 1.05 (0.96-1.14) 0.94 (0.86-1.02) 0.93 (0.85-1.02)
366-1095 267 (0.5) 938 (0.4) 1.11 (0.97-1.27) 0.98 (0.85-1.12) 0.93 (0.80-1.09)
>1095 282 (0.5) 943 (0.4) 1.19 (1.04-1.36) 1.03 (0.90-1.18) 1.04 (0.90-1.20)
(continued)
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bias due to nonresponse, and data were recorded prospec-
tively, so results are not susceptible to recall bias. Compre-
hensive data on prescriptions meant that we could derive a
measure of total anticholinergic drug exposure, which ac-
counted for the quantity and dose prescribed.
Ourfindingsareconsistentwithotherstudies, includingaUS
cohort studyof3434participants,11which reportedahazard ra-
tio of 1.54 (95%CI, 1.21-1.96) for the highest exposure category
(>1095TSDDs),similartoourAORof1.49(95%CI,1.44-1.54).With
our largersamplesizewecouldalsoexaminespecific typesofan-
ticholinergicdrugsandaccount forabroaderrangeofconfound-
ers.AstudybyRichardsonetal,12usinganotherUnitedKingdom
primarycaredatabase (CPRD), reportedfindingssimilar toours,
despite somedifferences in thedrugs included, exposuremea-
sures used, exposurewindows, and the confounding variables
accounted for. For example, we included drugs based on those
identified as having strong anticholinergic properties by the
American Geriatrics Society 2012 Beers Criteria Update Expert
Panel,14 whereas Richardson et al12 used drugs included in the
2012updateoftheAnticholinergicCognitiveBurdenscale.35While
bothCPRDandQResearchare largeUnitedKingdomdatabases,
QResearch is themost nationally representative,while CPRD is
moregeographicallyrestricted.36Despitethesedifferences,Rich-
ardsonetal12alsofoundincreases indementiariskforthegroups
ofantidepressant,urological,andantiparkinsondrugsconsidered
andnoassociations forgastrointestinalor antihistaminedrugs.
Thecoherenceof findings in these3studiesprovidesstrongevi-
denceforreliabilityandrobustnessoftheassociationsacrossdif-
ferent studydesigns, countries, and settings.Nevertheless, the
possibilityof residual confoundingremains,and it is impossible
toentirelyexcludeprotopathiceffectsarisingfromtreatmentfor
very early preclinical effects of dementia.
Limitations
A limitation is that somepatientsmaynothave taken theirpre-
scribedmedication or not taken the dose prescribed, leading
to exposure misclassification. This misclassification, if non-
differential, would tend to reduce ORs andmight explain the
lack of association for antihistamines and the highest expo-
sure category of antivertigo drugs. Our identification of pa-
tientswithdementiawasbasedonrecordeddiagnosesor treat-
ment with acetylcholinesterase-inhibiting drugs rather than
screeningof theentire studypopulation.Thismeans that there
will be underascertainment of dementia cases, so some con-
trolsmayhavehadundiagnoseddementia,whichagainwould
tend to underestimate associations with drug exposure.
The analysis accounted for a wide range of potential con-
founding variables, but in an observational study, there is po-
tential for residual confounding and indication bias. We en-
deavored to reduceprotopathicbiasbyexcludingprescriptions
in the year before diagnosis and in the 3 and 5 years before di-
agnosis in sensitivity analyses. The increased risks identified
for specific druggroups in themainanalysis remained in these
sensitivity analyses except for the association with antipsy-
chotic drugs,whichwasnot significantwhenprescriptions in
the5yearsbeforediagnosiswereexcluded, suggesting that the
associationmay be due to protopathic bias. Some bias due to
prescriptions for prodromal symptoms occurring more than
5 years before diagnosis may remain because, while there is
an average of 1 to 5 years between onset of symptoms and de-
mentia diagnosis,37,38 some early symptoms such as cogni-
tive decline and depression can start to emerge up to 10 years
before diagnosis.39,40 There is ongoingdebate, however, as to
whether depression is a risk factor for dementia rather than a
prodromal symptom.1,41
Table 5. ORs for Total Cumulative Use of Different Types of Anticholinergic Drugs
in the 1 to 11 Years Before the Index Date (continued)
Drug Type
Study Participants, No. (%) Odds Ratio (95%CI)
Case Patients
(n = 58 769)
Controls
(n = 225 574) Unadjusted
Adjusted for the
Other Drug Typesa Fully Adjustedb
Antiarrhythmics, TSDDs
Nonuse 58 720 (99.9) 225 402 (99.9) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 9 (0) 37 (0) 0.88 (0.42-1.84) 0.88 (0.42-1.84) 0.74 (0.33-1.64)
91-365 7 (0) 20 (0) 1.38 (0.58-3.28) 1.35 (0.57-3.22) 1.25 (0.44-3.53)
366-1095 10 (0) 27 (0) 1.22 (0.58-2.56) 1.16 (0.55-2.46) 1.22 (0.56-2.66)
>1095 23 (0) 88 (0) 0.97 (0.61-1.55) 0.99 (0.62-1.58) 0.94 (0.56-1.55)
Antiepileptics, TSDDs
Nonuse 57 358 (97.6) 221 082 (98) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 630 (1.1) 2459 (1.1) 0.98 (0.90-1.07) 0.89 (0.81-0.97) 0.88 (0.80-0.97)
91-365 202 (0.3) 592 (0.3) 1.31 (1.12-1.54) 1.17 (1.00-1.38) 1.14 (0.95-1.36)
366-1095 135 (0.2) 359 (0.2) 1.42 (1.16-1.74) 1.25 (1.02-1.53) 1.13 (0.90-1.41)
>1095 444 (0.8) 1082 (0.5) 1.58 (1.41-1.77) 1.44 (1.28-1.61) 1.39 (1.22-1.57)
Antimuscarinic Bronchodilators, TSDDs
Nonuse 54 891 (93.4) 211 578 (93.8) 1 [Reference] 1 [Reference] 1 [Reference]
1-90 1228 (2.1) 4326 (1.9) 1.10 (1.03-1.17) 1.05 (0.99-1.13) 0.99 (0.92-1.07)
91-365 786 (1.3) 2885 (1.3) 1.05 (0.97-1.14) 1.01 (0.93-1.09) 0.97 (0.89-1.06)
366-1095 742 (1.3) 2719 (1.2) 1.07 (0.99-1.16) 1.02 (0.94-1.11) 0.97 (0.88-1.06)
>1095 1122 (1.9) 4066 (1.8) 1.08 (1.01-1.16) 1.05 (0.98-1.13) 0.97 (0.90-1.05)
Abbreviations: OR, odds ratio;
TSDD, total standardized daily dose.
a Adjusted for other anticholinergic
drug types andmatching by age, sex,
general practice, and calendar time.
bAdjusted for other anticholinergic
drug types, bodymass index,
calculated asweight in kilograms
divided by height inmeters squared,
smoking status, alcohol
consumption, Townsend deprivation
score, ethnic group, coronary heart
disease, atrial fibrillation, heart
failure, hypertension,
hyperlipidemia, diabetes (type 1 and
type 2), stroke, transient ischemic
attack, subarachnoid hemorrhage,
renal disease, asthma, chronic
obstructive pulmonary disease,
anxiety, depression, bipolar disorder,
schizophrenia, severe head injury,
cognitive decline/memory loss,
antihypertensive drugs, aspirin,
hypnotics, anxiolytic drugs,
nonsteroidal antiinflammatory
drugs, statins, andmatching by
age, sex, general practice, and
calendar time.
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Conclusions
The present study adds further evidence of potential risks as-
sociatedwith strong anticholinergic drugs, particularly those
that are antidepressants, bladder antimuscarinic drugs, anti-
parkinson drugs, and epilepsy drugs. Adverse effects should
be considered alongside benefits when these drugs are pre-
scribed,andalternative treatmentsshouldbeconsideredwhere
possible, such as other types of antidepressant or nonphar-
macological treatments for depression, alternative antipar-
kinsonian drugs, and bladder training or mirabegron for
overactivebladders.42,43We foundgreater increases in risk as-
sociatedwith people diagnosedwithdementia before the age
of80,which indicates thatanticholinergicdrugs shouldbepre-
scribed with caution in middle-aged and older people.
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